Loading…
← CockpitCompetitor Analysis › 7799.TW Heron Neutron Medical Corp.Open in the cockpit ↗

Heron Neutron Medical Corp.7799.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Industrials›Miscellaneous Commercial Services

Taiwan medical-device developer building accelerator-based Boron Neutron Capture Therapy (BNCT) systems for cancer treatment.

Momentum leader 98
Mkt cap
$2.15B
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$7.13M
20-day average traded
P/B
6.38×
price to book
ROE
-3.1%
delivered
Implied ROE
23.6%
what the price asks
Next earnings
134 days
1 Apr 2027
Close · TWDNT$476.00
1D-1.9%
1W+10.2%
1M+5.1%
3M+29.7%
6M+56.1%
YTD+5.4%
1Y-28.3%
ATR %6.1%
52w lowhigh29.9% off high

What Heron Neutron Medical does

Taiwan medical-device developer building accelerator-based Boron Neutron Capture Therapy (BNCT) systems for cancer treatment.

Sells treatment systems built around a particle accelerator, so each sale is a single large project that can take years from order to hospital installation, with ongoing service after that. Its income waits on regulatory approvals and installations.

Products and services

  • BNCT accelerator systems
  • Treatment planning/support equipment

Customers

  • Hospitals & cancer treatment centers

Where it sits in the supply chain

  • Healthcare equipment
  • Radiation oncology
  • Neutron therapy systems

What could go right

  • Adoption of BNCT for recurrent/head-neck cancers

What could go wrong

  • Regulatory approval timelines
  • Slow clinical adoption

Moat: narrow (IP / patents, regulatory licence). BNCT requires specialized accelerator technology and regulatory clearance, limiting competitors.

Headquarters: Hsinchu, Taiwan · Employees: 111

Named competitors

Heron Neutron Medical at a glance

Size Heron Neutron Medical (7799.TW) is a Taiwan Industrials company (Miscellaneous Commercial Services) with a market value of $2.15B, the 153rd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$476.00 on 18 Nov 2026.

Performance Over six months the shares gained 56.1%, against -4.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 21 in its peer set.

Growth The operating margin is -5,318.9% (peer median 15.5%).

Valuation It trades at 6.38× book value against a peer median of 3.17× (6th most expensive of 21).

Price implies The share price implies a return on equity of about 23.6%; Heron Neutron Medical delivers -3.1%, so the price asks more than the business earns today.

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 20267799.TW 153Peer median 95
Six months, rebased to 100: Heron Neutron Medical against the median of its 20 peers (local-currency closes).

Heron Neutron Medical financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$9.61MNT$10.3MNT$0NT$238,000NT$0
Revenue growth——-100%——
Gross profit-NT$60.0M-NT$63.1M-NT$24.2M-NT$15.3M-NT$14.0M
EBITDA-NT$463M-NT$495M-NT$238M-NT$114M-NT$73.8M
Net income-NT$365M-NT$482M-NT$260M-NT$126M-NT$86.2M
Free cash flow-NT$92.9M-NT$512M-NT$309M-NT$260M-NT$355M
Capital expenditureNT$652MNT$30.1MNT$49.0MNT$56.2MNT$114M
Total debtNT$240MNT$7.23MNT$9.51MNT$13.4MNT$17.3M

Quarterly statements and history in the cockpit →

Heron Neutron Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%TIC32646257688796688690IGILSAGILITYFSL001267KWS601965300140688596VVXSYNGENE002091NSP4194605376PSG7799.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Heron Neutron Medical is the large dot.

Fundamentals: return on equity against price-to-book

0%10%20%50×100×TIC32646257688796688690IGILSAGILITYFSL001267KWS601965300140688596SYNGENE002091NSP4194605376PSG7799.TWReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Heron Neutron Medical is the large dot.

Capital: ROE delivered against the ROE the price implies

0%50%100%150%200%0%100%200%TIC32646257688796688690FSL001267KWS688596NSP41946053767799.TWROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Heron Neutron Medical is the large dot.

Heron Neutron Medical competitors and peer comparison

Head to head with its named competitors (7799.TW vs 6302.T)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Heron Neutron Medical 7799.TW$2.15B+56%n/a-3%6.38×23.6%
Sumitomo Heavy Industries 6302.T$3.62B-9%+9%6%0.81×10.9%

How Heron Neutron Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Heron Neutron Medical against its 20 peers (data as of 18 Nov 2026)
Measure7799.TWPeer medianRank in peer set
1-month return+5.1%-1.1%6th highest of 21
6-month return+56.1%-4.4%highest of 21
Return on equity-3.1%11.5%2nd lowest of 21
Price / book6.38×3.17×6th most expensive of 21
ROE the price implies23.6%21.6%11th least demanding of 21
ROE delivered-3.1%10.7%2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Heron Neutron Medical 7799.TWTaiwan$2.15B+56%n/a-3%6.38×23.6%-3.1%
TIC Solutions TICUnited States$2.15B+14%+39%-6%1.02×13.9%-5.5%
Ardentec 3264.TWOTaiwan$2.17B-26%+32%21%3.04×24.6%20.7%
Sigurd Microelectronics 6257.TWTaiwan$2.10B-28%+18%20%2.59×18.0%20.0%
Biocytogen Pharmaceuticals (Beijing) 688796.SSChina$2.09B-33%+40%22%11.62×126.9%21.8%
Suzhou Nanomicro Technology 688690.SSChina$2.08B-1%+26%12%6.37×70.8%12.3%
International Gemological Institute IGIL.NSIndia$2.05B+33%+21%45%10.96×103.5%n/a
Sagility SAGILITY.NSIndia$2.26B+7%+28%11%2.07×18.5%10.7%
Firstsource Solutions FSL.NSIndia$2.04B+13%+20%16%3.86×46.7%15.7%
Hui Lyu Ecological Technology Groups 001267.SZChina$2.28B-68%+90%6%9.25×72.1%6.0%
KWS SAAT SE & Co KGaA KWS.DEGermany$2.30B-11%-1%8%1.24×5.4%8.0%
China Automotive Engineering Research Institute 601965.SSChina$2.31B-11%+12%14%1.84×9.6%13.7%
CECEP Environmental Protection 300140.SZChina$2.37B-23%-2%6%1.08×9.3%6.3%
Shanghai GenTech 688596.SSChina$2.37B+4%+4%8%3.31×32.4%8.1%
V2X VVXUnited States$2.45B+9%+13%9%2.10×10.5%8.8%
Syngene International SYNGENE.NSIndia$1.88B-8%-6%4%3.60×48.0%3.9%
Jiangsu Guotai International 002091.SZChina$1.87B-15%+7%7%0.76×6.0%6.9%
Insperity NSPUnited States$1.86B+55%+2%5%41.04×190.7%4.6%
Visional 4194.TJapan$2.50B+33%+24%24%4.61×15.6%24.1%
Jiangsu Boqian New Materials Stock 605376.SSChina$2.52B-46%+76%17%8.77×139.5%16.5%
Prosegur Compania de Seguridad PSG.MCSpain$1.82B+10%+4%16%2.03×16.4%16.1%

Questions

Who are Heron Neutron Medical's main competitors?
Named competitors: Sumitomo Heavy Industries (6302.T), Neutron Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes TIC Solutions (TIC), Ardentec (3264.TWO), Sigurd Microelectronics (6257.TW), Biocytogen Pharmaceuticals (Beijing) (688796.SS), Suzhou Nanomicro Technology (688690.SS), International Gemological Institute (IGIL.NS).
Is Heron Neutron Medical expensive compared with its peers?
On price / book it trades at 6.38× against a peer median of 3.17×, 6th most expensive of 21 in its peer set. The share price implies a return on equity of about 23.6%; Heron Neutron Medical delivers -3.1%, so the price asks more than the business earns today.
How has Heron Neutron Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +56.1% against -4.4% for the median peer; over one year -28.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.